Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
17.21
-0.76 (-4.23%)
At close: Mar 20, 2026, 4:00 PM EDT
17.52
+0.31 (1.78%)
After-hours: Mar 20, 2026, 7:54 PM EDT
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 20 analysts that cover Apellis Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $31.65, which forecasts a 83.90% increase in the stock price over the next year. The lowest target is $18 and the highest is $52.
Price Target: $31.65 (+83.90%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 6 | 6 | 7 |
| Buy | 7 | 7 | 6 | 5 | 5 | 5 |
| Hold | 8 | 9 | 8 | 8 | 8 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 20 | 21 | 20 | 20 | 20 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $35 → $31 | Buy | Maintains | $35 → $31 | +80.13% | Mar 18, 2026 |
| Roth Capital | Roth Capital | Strong Sell → Strong Buy Initiates $31 | Strong Sell → Strong Buy | Initiates | $31 | +80.13% | Mar 13, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +114.99% | Mar 5, 2026 |
| Mizuho | Mizuho | Hold Maintains $19 → $20 | Hold | Maintains | $19 → $20 | +16.21% | Mar 5, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $45 → $44 | Strong Buy | Maintains | $45 → $44 | +155.67% | Feb 25, 2026 |
Financial Forecast
Revenue This Year
878.95M
from 1.00B
Decreased by -12.44%
Revenue Next Year
1.04B
from 878.95M
Increased by 18.21%
EPS This Year
-1.19
from 0.17
EPS Next Year
-0.33
from -1.19
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 975.6M | 1.2B | |||
| Avg | 879.0M | 1.0B | |||
| Low | 778.6M | 855.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.8% | 34.8% | |||
| Avg | -12.4% | 18.2% | |||
| Low | -22.4% | -2.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.38 | 1.09 | |||
| Avg | -1.19 | -0.33 | |||
| Low | -2.15 | -1.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.